A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Summary

The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.

Timeline

Start

2019-02-12

Primary completion

2020-01-17

Completion

2020-07-22

Outcome

Missed primary endpoint

registry p = 0.1492; Mean Difference (Final Values) -25.6 (90% CI -54.9 to 3.7) NCT03822832 ↗

Drugs

Indications